Ортопедическая и мышечная система: текущие исследования
Открытый доступ
ISSN: 2161-0533
ISSN: 2161-0533
Milena Favara, Annalisa Curcio, Fabiana Nano, Matteo Rossi, Marco Vettore, Adriana Romano and Michele Pironti
Objective: The aim of this study is to evaluate the analgesic effect of the new lipogel formulation based on Cannabis sativa oil enriched in CBD, escin, bromelain, Boswellia extract, glucosamine sulphate, MethylSulfonylMethane (MSM) and methylsalicylate (Cibides lipogel®), in patients with localized pain related to acute minor musculoskeletal conditions.
Methods: In this study 60 patients with pain due to one of the following conditions: tendinitis of the upper or lower limbs, low back pain, knee and ankle sprains/contusions, sport-related soft-tissue injury (sprains, strains and contusions) of upper or lower limbs, cervicalgia (neck pain), myalgias, arthrosis, carpal-tunnel syndrome, were included in the evaluation. Patients were allocated to treatment with the new lipogel formulation three times a day for 7 days and were evaluated at 5 timings: T0 (baseline), T1 (30 minutes after first application), T2 (1 day after first application), T3 (3 days after first application) and T4 (7 days after first application) by assigning a score in a 100-mm Visual Analogue Scale (VAS). The primary objective was to assess the analgesic effect by using the reduction of VAS score from T0 to T4. The secondary outcome was to obtain information on the safety of locally applied product.
Results: The results showed a statistically significant VAS score reduction versus baseline for each time point evaluated, with a mean reduction from 77.52 registered at T0 to 30.55 registered at T4 (P<0.001). The mean VAS score from T0 to T4 was reduced of about 47%. Regarding the secondary safety outcome, the gel application was well tolerated, and no adverse events were reported.
Conclusion: This study confirmed the analgesic effect of a new topical composition based on Cannabis sativa oil enriched in CBD, escin, bromelain, Boswellia extract, glucosamine sulphate, MethylSulfonylMethane (MSM) and methylsalicylate (Cibides lipogel®), in patients with localized pain related to acute minor musculoskeletal conditions.